Cannabis chemicals join fight against deadly brain tumor
NCT ID NCT03529448
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tested whether adding THC and CBD (cannabinoids from cannabis) to standard chemotherapy and radiation is safe for people with newly diagnosed glioblastoma, an aggressive brain cancer. Thirty-three patients received gradually increasing doses of the cannabinoid combination alongside their usual treatment. The main goal was to find the highest safe dose and track any side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
THC (tetrahydrocannabinol) and CBD (cannabidiol) combined with temozolomide and radiotherapy
What this could lead to
If it works, this could point toward a new way to improve standard treatment for glioblastoma, potentially extending survival.
What could go wrong
This is an early, small trial (33 people) focused on safety, not effectiveness. The added cannabinoids may not improve outcomes and could cause side effects like dizziness or fatigue.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Complejo Hospitalario Regional Virgen de las Nieves
Granada, 18004, Spain
-
Hospital Clínico Universitario de Salamanca
Salamanca, 37007, Spain
-
Hospital Regional Universitario de Malaga
Málaga, Spain
-
Hospital Universitario 12 de Octubre
Madrid, 28041, Spain
-
Hospital Universitario Son Espases
Palma de Mallorca, Mallorca, Spain
-
Hospital Universitario Virgen del Rocío
Seville, Andalusia, 41013, Spain
-
Hospital del Mar
Barcelona, 08003, Spain
-
Institut Català d'Oncología L'Hospitalet
L'Hospitalet de Llobregat, Barcelona, 08908, Spain